NCT05369000 - Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

June 18, 2025

Study Completion Date

June 18, 2025

Conditions

Metastatic Castration Resistant Prostate Cancer

Interventions

BIOLOGICAL

LAVA-1207

"In part 1 \& part 2~• LAVA-1207 will be administered via intravenous infusion."

BIOLOGICAL

LAVA-1207 plus Pembrolizumab

Pembrolizumab will be administered via intravenous infusion

Trial Locations (12)

NYU Langone Health, New York

Duke University Medical Center - Duke Cancer Center, Durham

Hospital Universitartio 12 De Octubre, Madrid

Centro Integral Oncologico Clara Campal (HM CIOCC), Madrid

M Health Fairview University of Minnesota Medical Center, Minneapolis

Washington University School of Medicine in St. Louis, St Louis

Huntsman Cancer Institute, University of Utah, Salt Lake City

UCSF Medical Center at Parnassus, San Francisco

Radboud Universiteit - Radboud Universitair Medisch Centrum (Radboudumc), Nijmegen

Erasmus MC (Erasmus Universitair Medisch Centrum Rotterdam), Rotterdam

Amsterdam UMC - VU Medisch Centrum (VUmc), Amsterdam

ICO Hospitalet (Hospital Duran i Reynals), Barcelona